Evofem Biosciences EVFM

Evofem Biosciences is a San Diego-based commercial-stage biopharmaceutical company focused on commercializing innovative products for women’s sexual and reproductive health. Its primary activities center on the development, commercialization, and marketing of prescription contraceptive and anti-infective therapies. The company addresses unmet needs in areas such as contraception, bacterial vaginosis, and trichomoniasis through targeted solutions.

Evofem Biosciences generates revenue primarily through the sale of its two FDA-approved commercial products: PHEXX and SOLOSEC. PHEXX is a hormone-free, on-demand prescription contraceptive vaginal gel used to prevent pregnancy. SOLOSEC is a single-dose oral antimicrobial agent indicated for the treatment of bacterial vaginosis and trichomoniasis. Revenue is derived from product sales in the United States and through licensing agreements with partners in international markets such as the Middle East and North Africa.

The company operates through the following segments:

• PHEXX: This segment encompasses the commercialization of PHEXX vaginal gel, the first and only FDA-approved non-hormonal prescription contraceptive gel available in the U. S. PHEXX works by maintaining vaginal pH to reduce sperm motility and prevent pregnancy. The product is sold in boxes of 12 pre-filled applicators and is marketed as a hormone-free, woman-controlled contraceptive option. The PHEXX trademark is central to this segment’s branding and market identity.
• SOLOSEC: This segment focuses on the commercialization of SOLOSEC oral granules, a single-dose treatment for bacterial vaginosis and trichomoniasis. SOLOSEC delivers a complete course of therapy with one 2-gram dose of secnidazole. The product is positioned as a convenient alternative to multi-day antibiotic regimens. The SOLOSEC trademark is used exclusively for this secnidazole-based therapy and supports the segment’s differentiation in the anti-infective market.

Within the women’s health pharmaceutical industry, Evofem Biosciences occupies a niche position as a provider of non-hormonal, on-demand contraceptive and single-dose anti-infective therapies. Its key competitors in contraception include manufacturers of hormonal products such as Organon (Nexplanon), Bayer (Mirena, Kyleena), and CooperSurgical (Paragard). In the anti-infective space, SOLOSEC competes with generic metronidazole and clindamycin therapies for bacterial vaginosis and trichomoniasis. The company’s competitive advantages stem from its unique mechanisms of action, FDA-first designations, and strong intellectual property portfolio protecting its core technologies.

Evofem Biosciences serves healthcare providers and patients in the women’s health sector. Its products are prescribed by obstetrician-gynecologists and other women’s healthcare professionals who treat contraceptive needs, bacterial vaginosis, and trichomoniasis. End users include women of reproductive age seeking hormone-free contraception or effective single-dose treatment for vaginal infections. The company also engages with managed care organizations, pharmacy benefit managers, and government payers regarding reimbursement and formulary placement for its products.